We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Gastric Cancer Detected Through Exhaled Breath

By LabMedica International staff writers
Posted on 27 Apr 2015
Print article
Image: Gas chromatography linked to mass spectrometry apparatus (Photo courtesy of the Hebrew University).
Image: Gas chromatography linked to mass spectrometry apparatus (Photo courtesy of the Hebrew University).
A new type of technology that senses minute changes in the levels of particular compounds in exhaled breath accurately identifies high risk changes which herald the development of stomach cancer.

The technology, known as nanoarray analysis, could be used not only to test for the presence of stomach cancer, but also to monitor those at high risk of subsequently developing the disease as stomach cancer rarely causes symptoms in its early stages, making it hard to detect.

Scientists at the Israel Institute of Technology (Haifa, Israel;) and their colleagues collected 968 breath samples from 484 patients, including 99 with gastric cancer, for two different analyses. The participants had fasted for 12 hours prior to the breath samples being taken and had refrained from smoking for at least three hours beforehand. In addition, subjects were tested for infection with Helicobacter pylori infection, an established risk factor for stomach cancer, and their smoking and drinking habits were analyzed.

The first sample was analyzed by gas chromatography linked to mass spectrometry (GCMS) and the second by cross-reactive nanoarrays combined with pattern recognition. The GCMS analysis that measures the levels of volatile organic compounds (VOCs) identified 130 VOCs in participants' exhaled breath. On comparing the breath samples of participants with stomach cancer with those of participants who had changes in VOC levels considered to be precancerous, the scientists identified eight distinctive "breath-print" compositions.

On applying the nanoarray technique to the breath samples, the team found it was effectively able to distinguish between breath-print compositions in participants with stomach cancer and those at low and high risk of the condition. The method achieved 73% sensitivity, 98% specificity and 92% accuracy, according to the results. While GCMS technology is unable to be used for stomach cancer screening due to its high cost and complexity, the scientists say nanoarray analysis may be a highly accurate and cheaper alternative. The study was published on April 13, 2015, in the journal Gut.

Related Links:

Israel Institute of Technology


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.